Latest Financial Disclosure News

Elanor Investors Group has extended the deadline for dispatching its Notice of Meeting related to the Rockworth Capital Partners transaction, with the Extraordinary General Meeting now expected in early February 2026.

Australian Ethical Investment Ltd has released its 2026 reporting calendar, outlining important dates for financial disclosures, dividends, and corporate governance events.

Locality Planning Energy Holdings has reached a confidential settlement over its Harbour Towers dispute, anticipating a net gain and cash inflow in FY2026. This resolution reverses prior impairment losses and signals a positive financial turn for the embedded energy provider.

Equus Energy Limited launches a $15 million public offer to fund the acquisition and development of the Equus Gas Project in Western Australia, backed by conditional funding from Alcoa. The project boasts a large independently certified contingent gas resource, positioning the company to address looming supply shortfalls in domestic and LNG markets.

Thorney Technologies Limited (ASX, TEK) will resume trading on the ASX from 16 December 2025 following the lodgement of its Net Tangible Asset Backing, ending its recent suspension.

AMP has reached an agreement in principle to settle a long-running class action over commissions paid between 2014 and 2021, agreeing to pay $29 million without admitting liability.

Novatti Group’s investment in AUDC Pty Ltd, issuer of the AUDD stablecoin, has nearly doubled in value following a $5 million Pre-Series A funding round led by a major global institutional investor.

The Federal Court of Australia has approved BHP’s AU$110 million settlement of the Samarco shareholder class action, marking a significant legal milestone for the mining giant.

Anteris Technologies has secured regulatory green lights for its pivotal PARADIGM trial and raised $25.2 million in capital, advancing its innovative DurAVR® transcatheter heart valve towards commercialisation.

Brightstar Resources has completed its merger with Aurumin Limited, acquiring all shares and issuing new Brightstar shares and options to Aurumin security holders on a 1-for-4 basis.

SDI Limited reported stable FY25 revenue with improved margins and advancing Montrose project, while regional sales showed mixed results.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.